Overview

Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To evaluate safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

Rosuvastatin Calcium